Earnings call briefSecond-quarter 2026

Gilead Sciences raises its 2026 HIV sales growth guidance to 9% to 10%

The company also raised the lower end of its total product sales range to $30.1 billion to $30.4 billion.

GetSignal August 4, 2026Gilead Sciences GILD

Gilead Sciences said on its second-quarter call that it now expects full-year 2026 base business sales to grow approximately 6% to 7% year-over-year, to between $29.8 billion and $30.1 billion, an increase of $350 million at the midpoint from its May guidance.

Chief Financial Officer Andrew Dickinson said the company expects non-GAAP EPS between negative $0.65 and negative $0.30 for the full year.

Quotes from the call

“With a $4 billion annual run rate for our PrEP business and Biktarvy's continued strength, we are raising our full year HIV growth expectations to 9% to 10% year-over-year from prior guidance of 8% growth.”

Daniel O'Day, Chairman and Chief Executive Officer

“We had strong second quarter base business performance and are updating our full year sales and EPS guidance as follows: We now expect base business sales to grow approximately 6% to 7% year-over-year and range between $29.8 billion and $30.1 billion.”

Andrew Dickinson, Chief Financial Officer